Advertise with us
[January 31, 2013]
Resverlogix comments on steady climb of share price
CALGARY, Jan. 31, 2013, 2013 (Canada NewsWire via COMTEX) -- TSX Exchange Symbol: RVX At the request of Market Surveillance, Resverlogix management has been requested to comment on the recent steady climb in the stock price.Management is unaware of any single factor for the increase. However we believe that the combination of a recent FDA approval of a competitive cholesterol management agent, mipomersen, and the anticipated pending completion of our Phase 2b ASSURE clinical trial may be primarily responsible for the increased activity.
About Resverlogix Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds arising from Resverlogix's epigenetic drug discovery platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including autoimmune diseases, cancer, neurodegenerative diseases and diabetes mellitus. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. Follow us on our blog at
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact: Company Contacts: Donald J. McCaffrey Sarah Zapotichny President and CEO Director of Investor Relations Resverlogix Corp. Resverlogix Corp.
Phone: 403-254-9252 Phone: 403-254-9252 Email: Email: email@example.com firstname.lastname@example.org SOURCE: Resverlogix Corp.
To view this news release in HTML formatting, please use the following URL:
SOURCE: Resverlogix Corp.
Back To NFVZone's Homepage